英文名稱 Anti-BSCL2/SPG17

中文名稱 先天性脂肪代謝障礙蛋白2抗體（常染色體顯性遺傳痙攣性截癱17）

濃 度 1mg/1ml

規 格 0.2ml/200μg

抗體來源 Rabbit

克隆類型 polyclonal

交叉反應 Human, Mouse, Rat, Dog, Cow, Horse, Rabbit

產品類型 一抗

研究領域 心血管 細胞生物 免疫學 神經生物學 細胞類型標志物

蛋白分子量 predicted molecular weight: 44kDa

性 狀 Lyophilized or Liquid

免 疫 原 KLH conjugated synthetic peptide derived from humanBSCL2/SPG17

亞 型 IgG

純化方法 affinity purified by Protein A

儲 存 液 Preservative: 15mM Sodium Azide, Constituents: 1%BSA, 0.01M PBS, pH 7.4

產品應用 WB=1:100-500 ELISA=1:500-1000 IP=1:20-100IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500

（石蠟切片需做抗原修復）

not yet tested in other applications.

optimal dilutions/concentrations should be determined by theend user.

保存條件 Store at -229 °C for oneyear.

別 名 Bernardinelli Seip congenital lipodystrophy 2;Bernardinelli Seip congenital lipodystrophy type 2 protein; Bernardinelli-Seipcongenital lipodystrophy type 2 protein; BSCL 2; BSCL2; BSCL2_HUMAN; GNG3LG;HMN 5; HMN5; MGC4694; Seipin; Spastic paraplegia 17 (autosomal dominant);Spastic paraplegia 17 (Silver syndrome); Spastic paraplegia 17; Spasticparaplegia with amyotrophy of hands and feet (Silver syndrome); Spasticparaplegia with amyotrophy of hands and feet; SPG 17; SPG17.